RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
vTv Therapeutics of North Carolina out-licensed China and Pacific Rim rights for a clinical-stage treatment aimed at inflammatory conditions to China’s Newsoara Biopharma. HPP737, a PDE4 Inhibitor, is expected to treat COPD and other inflammatory diseases. Newsoara will make an upfront payment along with development and commercialization milestones, plus royalties on sales. Based on Phase I trials, vTV believes HPP737 will be better tolerated than currently available PDE4 inhibitors.
Source: China Biotoday
